• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pediatr Pulmonol . Surfactant Protein D is a Biomarker of Influenza-Related Pediatric Lung Injury

tetano

Editor, Senior Moderator
Pediatr Pulmonol


. 2021 Nov 29.
doi: 10.1002/ppul.25776. Online ahead of print.
Surfactant Protein D is a Biomarker of Influenza-Related Pediatric Lung Injury


Arindam Chakrabarti[SUP] 1 [/SUP], Allen Nguyen[SUP] 2 [/SUP], Margaret M Newhams[SUP] 3 [/SUP], Maikke B Ohlson[SUP] 1 4 [/SUP], Xiaoying Yang[SUP] 5 [/SUP], Sheila Ulufatu[SUP] 6 [/SUP], Shannon Liu[SUP] 6 [/SUP], Summer Park[SUP] 7 [/SUP], Min Xu[SUP] 7 [/SUP], Jenny Jiang[SUP] 2 [/SUP], Wendy G Halpern[SUP] 8 [/SUP], Veronica G Anania[SUP] 2 [/SUP], Jacqueline M McBride[SUP] 2 [/SUP], Carrie M Rosenberger[SUP] 1 [/SUP], Adrienne G Randolph[SUP] 3 9 [/SUP], Pediatric Intensive Care Influenza (PICFLU) Investigators



Affiliations

Abstract

Background: Biomarkers that can risk-stratify children with influenza virus lower respiratory infection may identify patients for targeted intervention. Early elevation of alveolar-related proteins in the bloodstream in these patients could indicate more severe lung damage portending worse outcomes.
Methods: We used a mouse model of human influenza infection and evaluated relationships between lung pathophysiology and surfactant protein D (SP-D), SP-A, and Club cell protein 16 (CC16). We then measured SP-A, SP-D and CC16 levels in plasma samples from 94 children with influenza-associated acute respiratory failure (PICFLU cohort), excluding children with underlying conditions explaining disease severity. We tested for associations between levels of circulating proteins and disease severity including the diagnosis of acute respiratory distress syndrome (ARDS), mechanical ventilator, intensive care unit and hospital days, and hospital mortality.
Results: Circulating SP-D showed a greater increase than SP-A and CC16 in mice with increased alveolar-vascular permeability following influenza infection. In the PICFLU cohort, SP-D was associated with moderate-severe ARDS diagnosis (p=0.01) and with mechanical ventilator (r =0.45, p=0.002), ICU (r=0.44, p=0.002), and hospital days (r = 0.37, p=0.001) in influenza infected children without bacterial coinfection. Levels of SP-D were lower in children with secondary bacterial pneumonia (p=0.01) and not associated with outcomes. CC16 and SP-A levels did not differ with bacterial coinfection and were not consistently associated with severe outcomes.
Conclusions: SP-D has potential as an early circulating biomarker reflecting degree of lung damage caused directly by influenza virus infection in children. Secondary bacterial pneumonia alters SP-D biomarker performance. This article is protected by copyright. All rights reserved.

Keywords: ARDS; influenza virus; murine; pediatric; surfactant proteins.
 
Back
Top Bottom